STOCK TITAN

PRF Technologies (PRFX) CFO discloses existing stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

PRF Technologies Ltd. filed an initial ownership report for Chief Financial Officer Broder Eyal, showing existing stock option awards rather than new share purchases or sales. He holds options over 180 ordinary shares at an exercise price of $30.0000 expiring on October 10, 2034, fully vested on the grant date. He also holds options over 2,000 ordinary shares at an exercise price of $15.7500 expiring on February 20, 2035, with 500 options vested at appointment and the remaining 1,500 vesting in equal quarterly installments beginning on May 20, 2026, subject to his continued service.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Broder Eyal

(Last)(First)(Middle)
C/O PRF TECHNOLOGIES LTD.
65 YIGAL ALON ST.

(Street)
TEL AVIV6744316

(City)(State)(Zip)

ISRAEL

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
PRF Technologies Ltd. [ PRFX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2) (3)10/10/2034Ordinary Shares180$30D
Employee Stock Option (Right to Buy)(1)( 2) (4)02/20/2035Ordinary Shares2,000$15.75D
Explanation of Responses:
1. Options granted under the 2019 PainReform Option Plan.
2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee.
3. The grant date of this grant is October 10, 2024. This option grant is fully vested as of this date.
4. The grant date of this grant is February 20, 2025. 500 of the options were vested as of the date of appointment. The remaining 1,500 options will vest in equal quarterly installments beginning on May 20, 2026 until fully vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
/s/ Eyal Broder03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the PRFX Form 3 filing for Broder Eyal show?

The Form 3 for PRF Technologies (PRFX) shows Chief Financial Officer Broder Eyal’s existing stock option holdings. It reports two option grants over 180 and 2,000 ordinary shares, including exercise prices, expirations, and vesting terms, without indicating any recent share purchases or sales.

How many PRF Technologies options does CFO Broder Eyal hold?

CFO Broder Eyal holds stock options over 180 and 2,000 PRF Technologies ordinary shares. The 180-share grant is fully vested, while 500 of the 2,000-share grant are vested and 1,500 will vest in quarterly installments starting May 20, 2026.

What are the exercise prices and expirations of PRFX options held by the CFO?

The CFO’s options over 180 ordinary shares have an exercise price of $30.0000 and expire on October 10, 2034. His options over 2,000 ordinary shares have an exercise price of $15.7500 and expire on February 20, 2035, according to the filing.

How do the vesting terms work for Broder Eyal’s 2,000-share PRFX option grant?

For the 2,000-share grant, 500 options vested as of Broder Eyal’s appointment. The remaining 1,500 options will vest in equal quarterly installments beginning on May 20, 2026, fully vesting on the three-year anniversary of the February 20, 2025 grant date.

Are the PRFX options held under a specific plan mentioned in the filing?

Yes. The options are granted under the 2019 PainReform Option Plan. To qualify for certain Israeli tax benefits under Section 102, securities issued to an employee in connection with this plan must be registered in the name of a trustee, as described in the footnotes.

Does this PRFX Form 3 indicate any insider buying or selling activity?

The Form 3 does not show insider buying or selling. It records existing stock option holdings for CFO Broder Eyal, including exercise prices, expirations, and vesting schedules, but transaction data in the summary indicates no net purchases, sales, or option exercises reported in this filing.
PRF Technologies Ltd.

NASDAQ:PRFX

View PRFX Stock Overview

PRFX Rankings

PRFX Latest News

PRFX Latest SEC Filings

PRFX Stock Data

1.79M
742.49k
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv-Yafo